Aspirin And Dipyridamole (Aspirin And Dipyridamole)

Trade Name : Aspirin and Dipyridamole

NorthStar Rx LLC

CAPSULE, EXTENDED RELEASE

Strength 25200 mg/1mg/1

ASPIRIN; DIPYRIDAMOLE Platelet Aggregation Inhibitor [EPC],Decreased Platelet Aggregation [PE],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC],Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Aspirin And Dipyridamole (Aspirin And Dipyridamole) which is also known as Aspirin and Dipyridamole and Manufactured by NorthStar Rx LLC. It is available in strength of 25; 200 mg/1; mg/1 per ml. Read more

Aspirin And Dipyridamole (Aspirin And Dipyridamole) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

About GNH

No data

Warnings and Precautions, Stress testing with intravenous dipyridamole and other adenosinergic agents () 12/2019

Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. u00a0
Aspirin and extended-release dipyridamole capsules are a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis ()

Aspirin and dipyridamole n- Arrayn- capsulesn- are not interchangeable with the individual components of aspirin and dipyridamole tablets.
The recommended dose of aspirin and extended-release dipyridamole capsulesu00a0is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. Aspirin and extended-release dipyridamole capsules can be administered with or without food.
In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and headaches become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.
u2022 One capsule twice daily (morning and evening) with or without food ()
u2022 In case of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning; resume BID dosing within one week)
u2022 Do not chew capsule () n
u2022 Not interchangeable with the individual components of aspirin and dipyridamole tablets
u2022 Dispense in this unit-of-use container ()

25 mg aspirin and 200 mg extended-release dipyridamole capsule contains yellow to dark yellow colored extended-release pellets incorporating dipyridamole and white to off white round biconvex film coated tablet incorporating immediate-release aspirin, in sizeu20190xELu2019 hard gelatin capsule with orange colored cap and white to off white colored body, imprinted u2018339u2019 on the body and u2018RDYu2019 on cap with black ink.
Capsule: 25 mg aspirin and 200 mg extended-release dipyridamole ()

u2022 Hypersensitivity to any product ingredients ()
u2022 Patients with known allergy to NSAIDs ()
u2022 Patients with the syndrome of asthma, rhinitis, and nasal polyps ()

u2022 Aspirin and extended-release dipyridamole capsules increases the risk of bleeding ()
u2022 Avoid use in patients with severe hepatic or renal insufficiency (, )
u2022 Interrupt aspirin and extended-release dipyridamole capsules 24 to 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing (, )

The following adverse reactions are discussed elsewhere in the labeling:
u2022 Hypersensitivity n n n
u2022 Allergy n n n
u2022 Risk of Bleeding n n n
The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea ()

Adenosinergic agents (e.g. adenosine, regadenoson)u00a0
Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A-receptor agonist. The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing.u00a0
Angiotensin Converting Enzyme (ACE) Inhibitors
Because of the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. u00a0
Acetazolamide
Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. u00a0
Anticoagulants and Antiplatelets
Patients taking aspirin and extended-release dipyridamole capsules in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. u00a0
Anagrelide
Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding.
Anticonvulsants
Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. u00a0
Beta Blockers
The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. u00a0
Cholinesterase Inhibitors
Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
Diuretics
The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. u00a0
Methotrexate
Salicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired. u00a0
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function.u00a0
Oral Hypoglycemics
Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. u00a0
Uricosuric Agents (probenecid and sulfinpyrazone)
Salicylates antagonize the uricosuric action of uricosuric agents.
Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding ()
Decreased renal function can occur with co-administration with NSAIDs ()

Pregnancy Category D ()

Because of the dose ratio of dipyridamole to aspirin, overdosage of aspirin and extended-release dipyridamole capsules are likely to be dominated by signs and symptoms of dipyridamole overdose. In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential. u00a0
Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness, and dizziness may occur. A drop in blood pressure and tachycardia might also be observed. u00a0
Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. Severity of aspirin intoxication is determined by measuring the blood salicylate level. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 mg/mL. In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Plasma concentrations of aspirin above 300 mg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 mg/mL. A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 grams. u00a0
Treatment of overdose consists primarily of supporting vital functions, increasing drug elimination, and correcting acid-base disturbances. Consider gastric emptying and/or lavage as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage and/or emesis, administration of activated charcoal as a slurry may be beneficial if less than 3 hours have passed since ingestion. Charcoal absorption should not be employed prior to emesis and lavage. Follow acid-base status closely with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance. Administer replacement fluid intravenously and augment with correction of acidosis. Treatment may require the use of a vasopressor. Infusion of glucose may be required to control hypoglycemia. u00a0
Administration of xanthine derivatives (e.g., aminophylline) may reverse the vasodilatory effects of dipyridamole overdose. Plasma electrolytes and pH should be monitored serially to promote alkaline diuresis of salicylate if renal function is normal. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required to treat salicylic overdose; however, since dipyridamole is highly protein bound, dialysis is not likely to remove dipyridamole. Exchange transfusion may be indicated in infants and young children. u00a0

Aspirin and extended-release dipyridamole capsules are a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release form and 25 mg aspirin, as an immediate-release film-coated tablet. In addition, each capsule contains the following inactive ingredients: acacia, anhydrous lactose, colloidal silicon dioxide, dimethicone, hypromellose, hypromellose phthalate, lecithin, methacrylic acid copolymer, microcrystalline cellulose, polyvinyl alcohol, povidone, pregelatinized starch, stearic acid, talc, tartaric acid, titanium dioxide, triacetin and xanthan gum.u00a0u00a0
Each capsule shell contains FD&C yellow 6, gelatin, sodium lauryl sulfate, titanium dioxide and yellow iron oxide.
Imprinting ink contains black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
Dipyridamole Dipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:u00a0u00a0
Dipyridamole USP is an intensely yellow, crystalline powder or needles. It is practically insoluble in water, sparingly soluble in ethyl alcohol, very slightly soluble in acetone and ethyl acetate.u00a0u00a0
Aspirin
The antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy)-, and has the following structural formula:u00a0u00a0
Aspirin USP is a white crystals, commonly tabular or needle like, or white, crystalline powder. Slightly soluble in water, freely soluble in alcohol, soluble in chloroform and in ether, sparingly soluble in absolute ether.

No data

In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/mbasis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats. u00a0
Combinations of dipyridamole and aspirin (1:5 ratio) tested negative in the Ames test, in vivo chromosome aberration tests (in mice and hamsters), oral micronucleus tests (in mice and hamsters) and oral dominant lethal test (in mice). Aspirin, alone, induced chromosome aberrations in cultured human fibroblasts. Mutagenicity tests of dipyridamole alone with bacterial and mammalian cell systems were negative.u00a0
Combinations of dipyridamole and aspirin have not been evaluated for effects on fertility and reproductive performance. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/mbasis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1,250 mg/kg (more than 30 times the MRHD on a mg/mbasis). Aspirin inhibits ovulation in rats.

ESPS2 (European Stroke Prevention Study-2) was a double-blind, placebo-controlled, 24-month study in which 6602 patients over the age of 18 years had an ischemic stroke (76%) or transient ischemic attack (TIA, 24%) within three months prior to entry. Patients were enrolled in 13 European countries between February 1989 and May 1995 and were randomized to one of four treatment groups: Aspirin/extended-release dipyridamole 25 mg/200 mg; extended-release dipyridamole (ER-DP) 200 mg alone; aspirin (ASA) 25 mg alone; or placebo. The mean age in this population was 66.7 years with 58% of them being males. Patients received one capsule twice daily (morning and evening). Efficacy assessments included analyses of stroke (fatal or nonfatal) and death (from all causes) as confirmed by a blinded morbidity and mortality assessment group. There were no differences with regard to efficacy based on age or gender; patients who were older had a trend towards more events. u00a0
Stroke Endpoint
Aspirin and extended-release dipyridamole capsules reduced the risk of stroke by 22.1% compared to aspirin 50 mg/day alone (p = 0.008) and reduced the risk of stroke by 24.4% compared to extended-release dipyridamole 400 mg/day alone (p = 0.002) (Table 3). Aspirin and extended-release dipyridamole capsules reduced the risk of stroke by 36.8% compared to placebo (p <0.001).
Table 3 Summary of First Stroke (Fatal or Nonfatal): ESPS2: Intent-to-Treat Population
Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID.
Figure 1 ESPS2: Cumulative Stroke Rate (Fatal or Nonfatal)
Over 24 months of Follow-Up
Combined Stroke or Death Endpoint
In ESPS2, aspirin and extended-release dipyridamole capsules reduced the risk of stroke or death by 24.2% compared to placebo. u00a0
Aspirin and extended-release dipyridamole capsules reduced the risk of stroke or death by 12.1% compared to aspirinu00a0alone and by 10.3% compared to extended-release dipyridamole alone. These results were not statistically significant.
Death Endpoint
The incidence rate of all cause mortality was 11.3% for aspirin and extended-release dipyridamole capsules, 11% for aspirin alone, 11.4% for extended-release dipyridamole alone and 12.3% for placebo alone. The differences between the aspirin and extended-release dipyridamole capsules, aspirin alone and extended-release dipyridamole alone treatment groups were not statistically significant. These incidence rates for aspirin and extended-release dipyridamole capsules and aspirin alone are consistent with previous aspirin studies in stroke and TIA patients.

Aspirin and extended-release dipyridamole capsules are available as a hard gelatin capsule, with orange colored cap and white to off white colored body, containing yellow to dark yellow colored extended-release pellets incorporating dipyridamole and white to off white round biconvex film coated tablet incorporating immediate-release aspirin. The capsule body is imprinted with u2018339u2019 on the body and u2018RDYu2019 on cap with black ink. u00a0
Aspirin and extended-release dipyridamole capsules are supplied in unit-of-use bottles of 60s capsules. u00a0
Bottles of 60u2019s NDC 16714-964-01
Store at 20u00baC to 25u00baC (68u00baF to 77u00baF); [See USP Controlled Room Temperature]. Protect from excessive moisture.

Advise the patient to read the FDA-approved patient labeling (Patient Information).
u2022 Risk of Bleeding
Inform patients that as with other antiplatelet agents, there is a general risk of bleeding including intracranial and gastrointestinal bleeding. Inform patients about the signs and symptoms of bleeding, including occult bleeding. Tell patients to notify their physician if they are prescribed any drug which may increase risk of bleeding. u00a0Counsel patients who consume three or more alcoholic drinks daily about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. u00a0
u2022 Pregnancy
Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with aspirin and extended-release dipyridamole capsules [see Use in Specific Populations ()].u00a0 u00a0
u2022 Headaches
Some patients may experience headaches upon treatment initiation; these are usually transient. In case of intolerable headaches, tell patients to contact their physician. u00a0
u2022 Stress Test
Instruct patients who are scheduled to undergo a pharmacologic stress test to tell their healthcare provider that they are taking aspirin and extended-release dipyridamole capsules.
u2022 Dosage and Administration
Tell patients that aspirin and extended-release dipyridamole capsules should be swallowed whole, and not chewed or crushed. If you miss a dose, continue with your next dose on your regular schedule. Do not take a double dose. u00a0
u2022 Storage
Inform patients to protect aspirin and extended-release dipyridamole capsules from moisture. u00a0
Rx only
Manufactured for:
Northstar Rx LLC
Memphis, TN 38141
Manufactured by
Dr. Reddyu2019s Laboratories Limited
Bachupally u2013 500 090 INDIA
Revised: 1219

Aspirin and Extended-Release Dipyridamole n- Capsules
(as' pir in and dye'' pir id' a mole)
Read this Patient Information before you start taking aspirin and extended-release dipyridamole capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. n
What is aspirin and extended-release dipyridamole n- capsules?
Aspirin and extended-release dipyridamole capsule is a prescription medicine that contains aspirin and a medicine that is slowly released in your body, called dipyridamole. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a u201cmini-strokeu201d (transient ischemic attack or TIA) or stroke due to a blood clot.
It is not known if aspirin and extended-release dipyridamole capsules is safe and effective in children. See u201cn
Who should not take aspirin and extended-release dipyridamole n- capsules?
Do not take aspirin and extended-release dipyridamole n- capsules
u2022 are allergic to any of the ingredients in aspirin and extended-release dipyridamole capsules. See the end of this leaflet for a list of ingredients in aspirin and extended-release dipyridamole capsules.
u2022 are allergic to non-steroidal anti-inflammatory drugs (NSAIDs)
u2022 have asthma in combination with runny nose and nasal polyps u00a0
Do not give aspirin and extended-release dipyridamole n- capsules to a child or teenager with a viral illness. Reye syndrome, a life-threatening condition, can happen when aspirin (an ingredient in aspirin and extended-release dipyridamole n- capsules) is used in children and teenagers who have certain viral illnesses.
What should I tell my doctor before using aspirin and extended-release dipyridamole n- capsules?
Before taking aspirin and extended-release dipyridamole n- capsules, tell your healthcare provider if you:
u2022 have stomach ulcers
u2022 have a history of bleeding problems
u2022 have heart problems
u2022 have kidney or liver problems
u2022 have low blood pressure
u2022 have myasthenia gravis
u2022 have any other medical conditions
u2022 are pregnant or plan to become pregnant. You should not take aspirin and extended-release dipyridamole capsules during pregnancy without first talking to your healthcare provider. Tell your healthcare provider right away if you become pregnant while taking aspirin and extended-release dipyridamole capsules.
u2022 are breast-feeding or plan to breast-feed. Aspirin and dipyridamole can pass into your milk. Talk to your healthcare provider about the best way to feed your baby if you take aspirin and extended-release dipyridamole capsules. u00a0
Tell your doctor you are taking aspirin and extended-release dipyridamole capsules if you are scheduled to have a stress test for your heart.
Tell your doctor about all the medicines you take,
u2022 a medicine for high blood pressure, irregular heart beat, or heart failure
u2022 acetazolamide [Diamox]
u2022 any blood thinner medicines
u2022 warfarin sodium [Coumadin, Jantoven]
u2022 a heparin medicine
u2022 anagrelide [Agrylinn
u2022 a seizure medicine
u2022 a medicine for Alzheimeru2019s disease
u2022 a water pill
u2022 methotrexate sodium [Trexall]
u2022 aspirin or a non-steroidal anti-inflammatory drug (NSAIDs). You should not take NSAIDs during treatment n- with aspirin and extended-release dipyridamole capsules.
u2022 a medicine for diabetes
u2022 probenecid [Probalan, Col-Probenecid]
Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed above. u00a0
Know the medicines you take. Keep a list of them and show your healthcare provider and pharmacist when you get a new medicine. u00a0
How should I take aspirin and extended-release dipyridamole capsulesn- ?
u2022 Take aspirin and extended-release dipyridamole capsules exactly as prescribed. Your healthcare provider will tell you how many aspirin and extended-release dipyridamole capsules to take and when to take them.
u2022 Headaches are not uncommon when you first start taking aspirin and extended-release dipyridamole capsules, but often lessen as treatment continues. Tell your healthcare provider if you have a severe headache. Your healthcare provider may change the instructions for taking aspirin and extended-release dipyridamole capsules.
u2022 Swallow aspirin and extended-release dipyridamole capsules whole. Do not crush or chew the capsules.
u2022 You can take aspirin and extended-release dipyridamole capsules with or without food.
u2022 n
u2022 If you take more aspirin and extended-release dipyridamole capsules (overdose) than prescribed, call your healthcare provider or Poison Control Center, or get emergency help right away. n
Symptoms of an overdose of aspirin and extended-release dipyridamole capsulesn- include:
u2022 a warm feeling or flushing
u2022 sweating
u2022 restlessness
u2022 weakness or dizziness
u2022 a fast heart rate
u2022 ringing in the ears u00a0
What should I avoid while using aspirin and extended-release dipyridamole capsulesn- ?
u2022 heavy alcohol use.
What are the possible side effects of aspirin and extended-release dipyridamole capsulesn- ? n- u00a0
Aspirin and extended-release dipyridamole capsulesn- may cause serious side effects, including:
u2022 increased risk of bleeding.
u2022 bleeding into your brain (intracranial hemorrhage).
u2022 severe headache with drowsiness
u2022 confusion or memory change
u2022 pass out (become unconscious) u00a0
u2022 bleeding in your stomach or intestine.
u2022 stomach pain
u2022 heartburn or nausea
u2022 vomiting blood or vomit looks like u201ccoffee groundsu201d
u2022 red or bloody stools
u2022 black stools that look like tar u00a0
u2022 new or worsening chest pain in some people with heart disease.
u2022 liver problems,
u2022 loss of appetite
u2022 pale colored stool
u2022 stomach area (abdomen) pain
u2022 yellowing of your skin or whites of your eyes
u2022 dark urine
u2022 itching u00a0
Call your healthcare provider right away if you have any of the symptoms listed above. n
The most common side effects of aspirin and extended-release dipyridamole capsulesn- include:
u2022 headache
u2022 upset stomach
u2022 diarrhea u00a0
These are not all the possible side effects of aspirin and extended-release dipyridamole capsules. Tell your healthcare provider or pharmacist if you have any side effect that bothers you or that does not go away. u00a0
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDAu00ad1088. u00a0
How should I store aspirin and extended-release dipyridamole capsulesn- ?
u2022 Store aspirin and dipyridamole extended-release capsules at 20u00baC to 25u00baC (68u00baF to 77u00baF).
u2022 Keep aspirin and dipyridamole extended-release capsules dry.
Keep aspirin and extended-release dipyridamole capsulesn- and all medicines out of the reach of children.
General information about aspirin and extended-release dipyridamole capsules
Medicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do not use aspirin and extended-release dipyridamole capsules for a condition for which it was not prescribed. Do not give aspirin and extended-release dipyridamole capsules to other people, even if they have the same symptoms that you have. It may harm them.
This Patient Information summarizes the most important information about aspirin and extended-release dipyridamole capsules. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about aspirin and extended-release dipyridamole capsules that is written for health professionals.
For more information, call 1-844-375-6847u00a0u00a0
What are the ingredients in aspirin and extended-release dipyridamole capsulesn- ?
Active Ingredients: dipyridamole in an extended-release form and aspirin
Inactive Ingredients: acacia, anhydrous lactose, colloidal silicon dioxide, dimethicone, hypromellose, hypromellose phthalate, lecithin, methacrylic acid copolymer, microcrystalline cellulose, polyvinyl alcohol, povidone, pregelatinized starch, stearic acid, talc, tartaric acid, titanium dioxide, triacetin and xanthan gum.u00a0
Each capsule shell contains FD&C yellow 6, gelatin, sodium lauryl sulfate, titanium dioxide and yellow iron oxide.
Imprinting ink contains black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
Rx only
Manufactured for:
Northstar Rx LLC
Memphis, TN 38141
Manufactured by:
Dr. Reddyu2019s Laboratories Limited
Bachupally u2013 500 090 INDIA
Revised: 1219

Container: 60s count
Unvarnished Area Consists of 2D Barcode, Lot Number, Expiry Date and Serial Number

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Get Price

Aspirin And Dipyridamole (Aspirin And Dipyridamole)

Trade Name : Aspirin and Dipyridamole

CAPSULE, EXTENDED RELEASE

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what
you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Aspirin And Dipyridamole (Aspirin And Dipyridamole)

Trade Name : Aspirin and Dipyridamole

CAPSULE, EXTENDED RELEASE

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Can’t find what
you’re looking for?